ArticleTherapeutic advances in neurological disorders2024

SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis.

Xavier Montalban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.